1. Proteasome Inhibitor MG132 Induces Death Receptor

    Combined treatment with a proteasome inhibitor and tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) is a promising strategy for cancer therapy.

1 Item

To Top